<SEC-DOCUMENT>0001193125-15-095350.txt : 20150317
<SEC-HEADER>0001193125-15-095350.hdr.sgml : 20150317
<ACCEPTANCE-DATETIME>20150317160734
ACCESSION NUMBER:		0001193125-15-095350
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150312
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150317
DATE AS OF CHANGE:		20150317

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		15706427

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d890730d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (date of earliest event reported): March&nbsp;12, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name of Registrant as Specified in Its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Florida</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-12111</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-3667538</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1301 Concord Terrace</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sunrise, Florida 33323</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive office) (zip code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code <U>(954)&nbsp;384-0175</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.03</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2015, MEDNAX, Inc., a Florida corporation (the &#147;Company&#148;), entered into a second uncollared accelerated share repurchase
(&#147;ASR&#148;) agreement with JPMorgan Chase Bank, N.A. (&#147;JPMorgan&#148;), to repurchase an additional $200 million of the Company&#146;s common stock. The second ASR is being effectuated under the master confirmation between the Company and
JPMorgan dated December&nbsp;15, 2014, which was previously filed as Exhibit 10.30 to the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the second ASR, the Company made a $200 million payment to JPMorgan on March&nbsp;16, 2015 and received an aggregate initial delivery of
approximately 2.2 million shares of the Company&#146;s common stock on March&nbsp;17, 2015. The final number of shares to be repurchased will be based on the volume-weighted average share price of the Company&#146;s common stock during the term of
the second ASR agreement, minus a discount and subject to adjustments pursuant to the terms and conditions of the second ASR agreement. At settlement, under certain circumstances, JPMorgan may be required to deliver additional shares of common stock
to the Company or the Company may be required to deliver shares of its common stock or to make a cash payment, at its election, to JPMorgan. The final settlement of the transactions under the second ASR agreement is expected to occur within nine
months. The Company is funding the second ASR with borrowings under its existing $1.3 billion unsecured revolving credit facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second ASR
agreement contains customary terms for these types of transactions, including, but not limited to, the mechanisms to determine the number of shares or the amount of cash that will be delivered at settlement, the required timing of delivery of the
shares, the specific circumstances under which adjustments may be made to the transactions, the specific circumstances under which the transactions may be terminated prior to its scheduled maturity and various acknowledgements, representations and
warranties made by the Company and JPMorgan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The second ASR is being executed as part of an authorization by the Company&#146;s Board of Directors to
repurchase up to $600 million of the Company&#146;s common stock, announced on October&nbsp;30, 2014. Including shares to be repurchased under the two ASRs and open market purchases, the Company has substantially completed this authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $600 million authorization is incremental to the Company&#146;s existing authorization to repurchase its common stock up to an amount sufficient to offset
the dilutive impact from the issuance of shares under the Company&#146;s equity programs. The Company will continue to contemplate various methods to effect future share repurchases under its existing repurchase program, including, among others,
open-market purchases and additional accelerated share repurchase programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, JPMorgan and/or its affiliates have directly and
indirectly engaged, and may engage in the future, in transactions with the Company for which they have received, or may receive, customary compensation, fees and expense reimbursement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;12, 2015, the Company issued a press release announcing its
entry into the second ASR agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is hereby incorporated in this Current Report by reference. The information contained in this Item&nbsp;7.01, including Exhibit 99.1, shall not
be deemed &#147;filed&#148; with the Securities and Exchange Commission nor incorporated by reference in any registration statement or other document filed by the Company under the Securities Act of 1933, as amended, except as shall be expressly set
forth by specific reference in such filing. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>(d)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">99.1&#151;Press Release of MEDNAX, Inc. dated March&nbsp;12, 2015. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March 17, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vivian Lopez-Blanco</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Vivian Lopez-Blanco</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of MEDNAX, Inc. dated March 12, 2015.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d890730dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g890730ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Strategy and Investor Relations
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">954-384-0175, x-5692 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE </U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX
Commences Second $200 Million Accelerated Share Repurchase Program </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FORT LAUDERDALE, Fla., March&nbsp;12, 2015 &#150; MEDNAX, Inc. (NYSE: MD), the
national medical group specializing in neonatal, anesthesia, maternal-fetal, pediatric cardiology, and other pediatric physician services, today announced the commencement of a second $200 million accelerated share repurchase (ASR) program with
JPMorgan Chase Bank, N.A. This program follows the Company&#146;s first ASR that commenced in December, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the ASR, MEDNAX will
repurchase $200 million of its common stock, with an aggregate initial delivery of approximately 2.2&nbsp;million shares. The final number of shares to be repurchased will be based on the volume-weighted average share price of the company&#146;s
common stock during the term of the ASR, minus a discount. The final settlement of the transactions under the ASR is expected to occur in up to nine months. The Company is funding the ASR with borrowings under its credit facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ASR program is being executed as part of an authorization by MEDNAX&#146;s Board of Directors to repurchase up to $600 million of the Company&#146;s
common stock, announced on October&nbsp;30, 2014. Including shares to be repurchased under this ASR program and open market purchases, the Company has substantially completed this authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The $600 million authorization is incremental to the Company&#146;s existing authorization to repurchase its common stock up to an amount sufficient to offset
the dilutive impact from the issuance of shares under MEDNAX&#146;s equity programs. MEDNAX will continue to contemplate various methods to effect future share repurchases, including, among others, open-market purchases and additional accelerated
share repurchase programs. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national medical group that comprises the nation&#146;s leading providers of neonatal, anesthesia, maternal-fetal and pediatric medical and
surgical subspecialty services. The Company is reshaping the delivery of care within its specialties and subspecialties using evidence-based tools, continuous quality initiatives and clinical research to enhance patient outcomes and provide
high-quality, cost-effective care. Pediatrix Medical Group, a division of MEDNAX, was founded in 1979 and includes neonatal physicians who provide services at more than 370 neonatal intensive care units, and collaborate with affiliated
maternal-fetal medicine, pediatric cardiology, pediatric critical care and physician subspecialists to provide a clinical care continuum. Pediatrix is also the nation&#146;s largest provider of newborn hearing screens. American Anesthesiology, a
division of MEDNAX, was established in 2007 and includes more than 2,400 anesthesiologists and advanced practitioners who provide anesthesia care to patients in connection with surgical and other procedures as well as pain management. MEDNAX,
through its affiliated professional corporations, employs approximately 2,650 physicians in 34 states and Puerto Rico. Additional information is available at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in
this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities,
events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;believe&#148;, &#147;hope&#148;, &#147;may&#148;,
&#147;anticipate&#148;, &#147;should&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;will&#148;, &#147;expect&#148;, &#147;estimate&#148;, &#147;project&#148;, &#147;positioned&#148;, &#147;strategy&#148; and similar expressions, and are based on
assumptions and assessments made by MEDNAX&#146;s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any
forward-looking statements in this press release are made as of the date hereof, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in
MEDNAX&#146;s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled &#147;Risk Factors&#148;, as well MEDNAX&#146;s current reports on Form 8-K, filed with the Securities and Exchange
Commission. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g890730ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g890730ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````4```_^X`#D%D
M;V)E`&3``````?_;`(0``@("`@("`@("`@,"`@(#!`,"`@,$!00$!`0$!08%
M!04%!04&!@<'"`<'!@D)"@H)"0P,#`P,#`P,#`P,#`P,#`$#`P,%!`4)!@8)
M#0L)"PT/#@X.#@\/#`P,#`P/#PP,#`P,#`\,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,_\``$0@`@0#F`P$1``(1`0,1`?_$`+L```$#!0$!````````
M```````'"`D!`@0%!@,*`0`"`P$!````````````````!`(#!0$&$``!`P,"
M`P0&`PD(#`\!```!`@,$``4&$0<A,1)!41,(87&!(C(4D14)L4)2TB.55Q@9
MH<%B,[/3%E:"@R1$U"5%A29V%S?PT7)38W,T5'2$E*3$52<H$0`"`@$#`P,#
M!`$$`P```````0(#$3$2!"%!46$3%'$B,H&1,Q4%P=%"(Z&Q4O_:``P#`0`"
M$0,1`#\`G\H`*YD`HR`49`*,@%&0"C(!1D`HR`49`*,@6J[*-0,-R=#9?:BN
MRFFY+XU984H!2O2$GC47))]6246UE&6#QY:=U2R1+Z,@6'3XN7;QH;`0>^;]
M8_:+\Y:F+9)N4.*\6)]S:4E*$J!T5T(4=5!)X'2D)\^,'C'<;AQ)..X7.)(:
MEQ8\IA8<8DMI=86.U"QU)/T&GTTUT%,-:F11D`HR`49`*,@%&0"C(!1D`HR`
M49`*[D`H`*XP"@`KH!0`4`%`!0`4`%`!0`4`6GLKF`&%[H)O;.Y5T<?4\F>9
M3"[(XGJU\/1/A!G3^%KK[:PN2IJUX-:C;[8^:VF28%O,P%,M49HRP1Q\7H'7
M^[6W'JEGP93U9L*F<,9]!=8>:ZNCQ&U)\3NZ@1K[*BUT!-=AA2MO;DC)';3<
MKK;(</YI1?N[LUD(+165%0'5KU$'ES!K"?&DY[9-:YSDUO>CLZ9S]!\ME=MO
MU=#C6F6U-A0F6X[+S+B7!TMI"4ZE)/8*VX--83,N6=6;@<14R)6N@%`!0`4`
M%`!0`4`%`!0`4`%<8!70"@`H`*`"@`H`*`"@`H`H37`$-W8W3DX<XQ9+&TT]
M?)+7C.R'1U)CMDZ)/1]\5:'04ER^4ZUB.HUQ^/[G5C;5;G9RY,;GNWSYB2RH
MJ94XPA24$\PE)Y"LM\F;>?(^J()8[#F]I]SG,U;D6R[MML7Z"@.]37!N2T>:
MTCL4#\0'HK5XG)]WH]4(<GC^V^F@M5.BHT??7,KN+X,5@S785LCQT.SFV5=*
MGUKU/2M0X](&G"L?_(724E!/I@T>'4FMPW3I'2=3U`\M>/'OK.:3>1W+1O<?
MR.]8M<6;E9)CD60@^\SJ2V^D'4MK2>"@:LA;*IYB1G!6=)#^L,RF+F&/0KY%
M`:+Z2F3'UU+3R."T^K7EZ*WZ;E9!21CVUN$L'5BKBLK0`4`%`!0`4`%`!0`4
M`%`!7&`5T`H`*`"@`H`*`"@`H`M*M-?11GK@"TJU/W*XNH#5'<)1N7NEFIG2
MG8UHLJFV''63[ZG"@>&A*CR`]XFLGV??OEX1H^[[52\L;U<X9M]QN5O\3Q50
M9#S`=T^(-K*4DCT@#6L^2VN2\#D>J7J*)C[AP>^8)E\=:U6:]-^'+<UX)45J
M;?9/=H0E6G=3-7_7*$^SU_V*)+W%*+U'U!YM2$NI4"TI/6'!R*2->KU:5NY[
MF3@9AX36X.[]TE!OQ[-"<<=G.'B@1HC1;&I[EJ&HK%Z77MKL:G\56.XBSG0M
MU];?NM+=<+0'()*CTZ>RDGJ-)=!T&)8W:-P-H6[4VRVW>+,X^(TL`=:)`6IU
M!)YZ*2H`BM.FJ-M&.Z$+9NNW/8KY=94IH979I`4CY-]MU;2OO'3JVM/THH_Q
M[:4H^`YJ71CFP=2:U1`NH`*`"@`H`*`"@`H`*`"@`KC`*Z`4`%`!0`4`%`!0
M!345S(#6-P=V,PQ//GX+26$66$&5(@.-\9+*_C6%\]=>`TK+Y'*LKMQV-"GC
MPG#/<<)<<EM]ILS%YG+\%$IMHQ(Q_C'77@/#:0GF5$J`X>OE6A*U12;[B4:V
MY-'`6QI6V^&Y-D=^<0+Q<Y#]RFA)U`>>]UAA)[>D`<O35$5[%<I/5O)=+_MF
MHK09,Z^[)>?E/*U?DNK>?/\`#=)6K[M8<GEY-6*QA>!?]G85LS.P9+@M^:\>
M$VI$V"0?RC*W04J4VKF""D'VUH<1*V,JY::H2Y3<9;T*S_1+/XV.JPV+D,5<
M!?\`<[.2N!?SK,/M1X8'2I>G`'JIQ4V*.Q-8\]Q=VP<MV.IJ\BL5DVIVTOC=
ME;/S<UH153W3J\^\Z-`5*[N9`JNRN-%+VG83=MBSV&:A26TI25!)2`!J0.58
MW0U<H6;8[(W;/F3=J6X1`R)!96T>0D('4VH`]IU(-.\"QQGCR*\N&Z.?`XK"
M,:%GR?/[HA(2S=;@W\N@:?\`-I<<X#E[ZU5H45[9S?J(W6;HQ.R;R?'W+NNP
M-W:,Y>&TE2[>EP%P:<QH.T=W.F/<COVYZE?MRQG'0WP4#4T0+JZ`4`%`!0`4
M`%`!0`4`%<8!70"@`H`*`"@`H`*`.6RW*8&(6.7>Y^JD,:-QXX^-YY?!#:!W
MDU5=:JXY[EE<-\L#+\HW,RC))B'+C!@P50W.J''5%U>8[0"MS11/#M%8MO*G
M/7!J540BNF1:MI\3G9(8&X6779^]R0I9L,-Y74VP1J@NE(T'5S`&G"G>+5*?
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M?@<QFLN_X1<)&7VB,;OCL]"4Y-:`K1;*TCH3+9/_`"0`H>BM2^4J\SCU3U_W
M$*HQFMKU[#9L5O%OMF7?7T"%<,CO+[[JK%;"$H)=?)]Y]Q*E$].O8-*RZ9I6
M)KJ^P]9%N&&\+N/=QYN\(ML95^=;<NKR?$EMLC1IDJX^$CO".6O;6W5N:S+4
MRIN.<+0WU6D0H`*`"@`H`*`"@`H`*XP"N@%`!0`4`%`!0`4`<Q>+#;;G-MUT
MO"DN1+$')+$5W3P4O:<'U@\"4)UT]=4SK4FG+L3C)KHM1A^:7AO(<MR&]1&U
MJAO2262A)(2TV`A"U:#@#TGB:PKI;YR:7<UZEL@DQT.P%R^;PM^WJ5U.6J:X
MC^P<`4G3VZUI\">:_P!1#F1Q/]#>;V!1VXOJAK^3\)>O<`L59SOX60XO\B1A
MX'C;3&TJ+:ZV>N[P9$F2#S*WDGI.GJ":Y14E3CRCMT\V_J:WR]LK9PJ7U\-;
MH^D#_JT-H/[HJ/\`CUBO]27,>9_H+Q3XH-HW!MO]+-X<1L!!7$@1$RIH'$!M
M+BE*^GW:S+X>YR(KLAZA[:I2'+````#0`<!6GC`CG(U[S`V72YXE?FD^\^^F
MWR-!VA86V2?6HBLOGP^Z,A[B3Z-"I;L7/ZGV[OB^:Y4=,)O4Z>\]HFFN3+%+
MSX*:%FU?4;'LS+CVO<"T_6*/ET3HSK,)QY)3[[B1T%!4!J%<M167PY*-JRNP
M]RDW!X\CZ4\_NUNHR47UT`H`*`"@`H`*`"@`H`*XP"N@%`!0`4`%`!0`4`)3
MG.)Y?F*U6J/D$>QXTO026V$*7)>':%*)2`!W"E+ZK+'C.(E]5D8=<99OL8P+
M',6LILD.$B0S(21/D2$A;DA2ATJ*SI]`[*G5QXUQVI=",[Y3EN.(V8L*K*WF
M90DB`[>G6;;KR+3.O%)[0"O37T53PX;=WC)9R99:^AV.YEN7=L&R&W-)+CLE
MEM*$CGKXJ/WJMY4=U;7H5TSVS3.JM<5,:U6^%T]*&8C3)1W=*`DU=%=$B$G]
MS^IR^WEC7CV/?).MEMUV?-D+01IP<?64GVITJKCPV1)W3W2_0[RF"H3^TXXZ
MUG6393,:`+[$>#:U$ZGPFT];A`[.I2M/92L88LE-_1%TI_8HG?CD*:*3A<_Q
MU>2VF%#:0%NQ;E%EI)[`TK56GLJB^KW%CU+:9[99]#QW'QMW*,?;M[2/%\&?
M%E.L]JVVEZK2/6*YR:O<C@[19LEGT/?*\`QW+8,:'-C?*.V\@VN=$T:>CD<N
M@@<O17;*(V=L8.0NE#)O[#;YUK@,PI]U<O+C'NHG.H"'"D<@O0D*/IJ=<7%8
M;R0G)2>4L&[JPB%`!0`4`%`!0`4`%`#3_.+N5F6U6TB<GP:YMVJ]&\08AE.L
MA\>$\Z$K'2H@<J8XT(RE]PMRYRA7F)%S^NMYD./^FL77TVYKEZNKZ*>^+69W
MR[?)([Y-O,;<-Y\:NN/YI,9=W"Q=SKEK;0&1-@NJ_)2$-@G3I.B5\>=)<FG8
M\K0?XE[FL-]1ZH]=*9Z#:1'5YR?-/D.V-XLVWVV-UCQ,H2GY_*;FXT)`BL*!
M#,<()`ZUD]7H`]-/<;CJ2R]!'E\APZ1?49'^NOYD/ZZ1!W_XO:/L^*F?BP\"
M?R[?(?KK^9#^NT3\W-?C4?%AX#Y5OD/UU_,A_7:)^;FOQJ/BP\!\JWR'ZZ_F
M0_KM$_-S7XU'Q8>`^5;Y#]=?S(<OZ:PS_FYK\:CXL/`?+M\EH\ZGF/2.E&90
MVTC[U-M:`[SR5VT?$K78/EV__1U5B\^V_P!:G$_6;MBR:*-/$CRH*F5J`/8M
MMW@?[$UR7$K:)1YEB[Y'Q[+^>K;S<:="QO,8:MO<GFJ2S$5(=#UMD.G@$MR=
M$%"E$\`M('II2WB2@LK0<IYD9O#U,+SO;U;B[00]NGMO+VS:57]^>FYJ=CID
M!U+*&"UTDD:?&:[Q:XS;R@Y=LH)88P>-YW?,=&E1)#F609K4=Y"W8;EO0E+R
M$D%;:B%:C4<-:;^)#P(_+L\DR^SNZ^.[S8):LTQUY($E`:NUMU!=A3$`>*PX
M/0>*3VI(-9EL'"6'H:U5BLCN0I%P><CV^<^T>EUF,ZXV>>A2@D'3UBHQ1-Z-
MD#\KSJ>8]N9.:;S6(&V9<AMM/U<T=$H=4E(^+L`TK5^+#P8SY=F=20WR2;P[
M@[OXSG-QS^[M7>79KNU%MSK3"6`AI<="RDA).IZB32?*K5;6![AVRL3W/(B?
MG+\S^>X3N/;L#VPRDV$6""E_*9#++3Q=E21UMLGQ$JT"6RE7#M-6\;CJ2S)%
M7+Y$HRQ%X&C,^</S(,/,/JW'?DI9<2XJ*N)&"74I.I0HAL$`CAK3/Q8/L*KE
MV)]63H[>9I;=Q,(QG-;2X%PLBM[,Q*0=?#6M(+C9]*%:I/I%9,X;'M9L5SWQ
MRAEOG,SW?[:&19\XV_R9#.`W((@7B$N$A\V^9R;<4LD?DW>6IY*IKBPKLZ,5
MY4[(-..@Q9OSL^9!IQIPYA">#:TK\%<!L)<">)22%:Z*'#T4U\6&!/YEF29S
M9O=.R[Q;?6#.K,L(%Q9"+K`Z@5Q)C?NOL+T[4JUT[Q6;;!URP:M-F^*8VCSE
M^9>Z;/6ZS8?@4^.SG]^4)<F4XV'A`M[1U4M2"?B=(Z4@]FIJ_C<?>^NA1RN1
M[:PM2/A'G4\RKBVFFLO8D/.K2VQ%;MK9<=6L@(0D!1U*R=``*<^-5DS_`)=O
MDD)F99OKAVW^#0LPOAG9YD45ZZW5<=MB&5/J=:2W:6'G.IEM3;3BG%*5SZ"`
M*2482D\:#^^<8K+ZL46V;C95,V3R+(I%Y;9N%JN35M@99X6B7F%S&(ZGM".D
MJ2EQ2?$`Z-?>TT!J#@M^"Q62V-]Q.OM"O]PJ?]8;9_+"K.%^97SOXR$S3_CK
M3,G`H&UFX]ZVESVP9[85*5)LSP^>A`Z)EPW/=?CK[^M!('<K0U&<-\6F3JL]
MN643PYIY@,+QC9->\\2<U/M%PMR)&-L)4.J7,D)T8C@:ZZ^)P7W`$]E9$:G*
M6TV96I0W'S[Y%D5WR[(;WE.02U3KWD$MR;<I2C\2W3KH!V!(X`=E;"BHK:C#
M<M[;9IM.?J[*,!@=EY<_*Q)\PEBR&]Q\T1B_U!/;@JBKAF47.M"E=74'6].7
M=5'(O5;Q@8HXKM3>1Q?[-6Y_I;8_-*O\)JGYB_\`EE_P'Y1Q&X_D(G[>8+E.
M;.[F-71&,P5S56]-M+1>Z"!T]9D*Z>?/0U*'*4I8P1LX3A'.2/=M?6AM8&GB
M)"D\===1RIS`AV'D;.>33+MY\#MF?V;,K99H-S<>;;@2H[CCB"RKI)*DJ`XF
MEK.1&#PQNKBNR.4:_<[R5;T[;6J5?VXL/-K)!0IR:_9EK,IEM(U4XJ,M()2!
MSZ5$UV'*A)X"SAS@LZC1E!MYK30.-JTTUX'@>![P0?:-*9TT%4T]1U+V27[>
M_8:38KM<G;IF/E^ZKO;?%)6[<,>EE#,@*)XJ<B*;1H?P%#NI?"KGZ,94G;##
MUB-8"NI(4"%)(U2KO!XCV$5<*I90X/RW[\738;/6;LI;LK#;ZIN+F-G2=4EK
M7W)3:>7B-:^U/`U5?5[D?48XUWM2]"?9%XMN08JN^66:U<;3=;8N5;IS*@IM
MUIQHJ0I)'H-9&,2PS:34HY1\Q\[A<+F0><Z3Q_MRZW$NAY]]6R4#R'95;L'V
M@WOR^[O!BVX[</GI3A[FH+9`]I``I'E1S))&CPY;829&IE.3W+,\FO\`E]X<
M+ESR6>_<915]Z7UE8;U[D`](]`IZ,4EA&?*3DVV:`=NNO#@0017<$5U)9/LZ
M=SC+LV5[2W*23(L;QO..-K5_>DE6DAM(_@NZG0<@:S^9!Y4C3X%N4XDB>8XC
M8L[QB]8ADD)$ZRW^*Y%GQU=J5CFD]BDGB#V&DXR<7E#TH*2P]#YU-W]K[WL[
MN#>\$O84LP%^-9+D4Z)F07#^1?2?5P4!R/"MFNQ3CE&'96X2<6+'Y4O,6-AL
MBOS%\^8F8-D<9;TR`R.I35Q90?EW&TZ^[XA`0KUZU5?3[L<]RSC7^R^NC$`S
M_-[[N1FF19OD;Y?NV02E.N(!U#+(.C4=L=B$(X"KZX;5A%,[-[<F/@\AVP8R
M[(5;Q93!#N-8O(4SA\9X:IEW!O@J3H1H4,'X3VJT/92?*NPMJ&^%1N^YDOMQ
MM%JO4?Y2[6Z/<8H4%I9DMI<2%?A)Z@=".\5GQ>#5:3U/3ZJMGR'U5]71?JOP
M_"^K?!1\OT?@^%ITZ>C2NY.8&1_:%?[A4_ZPVS^6%,\+^1"?._C(27%AM"W%
M<$H!4?0`*TT97<['.,(O^WU\18<BC>#)DP8US@2$:EN1#EHZVGFE=NH.A'8:
MC"6_JCLXN#P^Y@R<JR*7BUJPF5=GWL6LDUZXVFRD_DF94@$..)]8)T!X#L%=
M45NSW.2D\8[&PQO![]D]BS7)K>P$V+`X;4R_7%8/AI,AY#++"3VN**]=.[6N
M2FHM)]R6UR3:[(XX'5*5<B1KT\R/74M2(MFU?F$W.V9MMTM.!7"%"A7B2F7.
M3*B^.I3J4E((5U)T&AY5793&QY9;5=*M-1[BI_KT^8S_`.]M'YN'\Y5?Q:_!
M9\RSRA2L*\QFZF\N#;]X]GEQ@SK9;,#D3XC46*(ZQ($J,V"5=2M1TK/"JYTQ
M@XM=V65\B5D9)]D1Y1_XEGTMHU^@?<IUZB'8G<\AXU\N&*_^,G?RE9/*7WFW
MQ/XT/$4D$$$=04""D\=1W4L,GSU^:W"K9@6_.<V:S,(AVF>XS=H<1L:(9,Q'
M4XE('(>(%$#TUL<>3<$S#Y,$IM'IY4I"O]M]BM"O?BY3:+S9+DR1JEQB1"6L
MA0Y:=30-=N6(?0.-^:0WV);'W;DS8XB0N2Y--MA(4=.IP/%EM.OI4`*L[%.O
M[F3>K/=,<O-TQ^^0G;9>;+*7$NEO?'2MIYLE*@0>P\P>1!%">5E:!)8ECNA]
M7DT\QQPQZ5M!F=P\/$\@;D#$;G(7[EOG+0HF,M1^%IWFGL2K7L/!7D4YQ*(Y
MQ>1MS%Z##+@%)N5T"QH1/E`CT^,NFT*/452V;C+LVQN5[8P5J1,S7*(]QO*Q
MP'U=$CM`-Z]H<<!!'HJMUYFI>A8K,0<?43W&<=N.7Y+CV*6AM3MTR2X,6^&A
M(U(4ZL))_L1K4IM),JK69)#TO._LC;]KYVVU]QN&&;#,L[..SUH2`#-MS02V
MZO3D76TC4GFK6EN+;ORAOF4;,8T&S;(;BO;4;K8;FZ%K$&W30Q>FT\/$@2=&
MY*?2>D]O;5]L-\-I33/;8I?H?2!$DQYL:/,B/(D19;:7H\ALZI6A8ZDJ![00
M=:Q6NO4W4\C0_.3L9%W8VXD7^W)9CYG@;+MPM,UPI0'HK:2N1%6L\DJ2"4D\
M`KC3/&MV2P]&*<NGW(>J()P20#R[ZUF9`I.T.VLW=W<7&]OX,MNW_73I,Z<M
M8068C(+D@MZ_$OH!Z1WU59/9%LG57OE@^C'$L5LF%XW9L4QV$BWV6PQ6XEOB
MMC0!#8TU/>3S)[36.Y;GDW81VK".C``Y5PD5H`8I]H5_N%3_`*PVS^6%-<+^
M1"7._C(1Y/\`$/'L#:CI[*TT9+T)FM^=@SN[Y>,#R''X@>SW!<>BR[/T#\I,
MBAA*GX?IZ@.I`_#`K-JMV68[&K=3[E:??!#Q:;3=;]=+?8++!=GWN[RDP;=;
MD@^(Y(=5T)3IV>]S/8.-:3:77L9:3ET[DOVX6S5NV1\DN:8FQT/WI^+#FY5=
M`D=4F>[,8+IUY]*/A2.P5F0L]RU&K95[=#1#B@^Z`.&H[/NUILR4/'\LGE8M
MWF"Q_)KU,R^7C2\?N*(+<>,PAX.)6@JZE%1'=2U]_M/&!OC\?W5G.!S?[-6Q
M_I4N?_HV?QJH^<_!?_7KR95P\IEO\O\`MAO;E4+,I>2.7C#9%K5"D1T-(0E3
M[#O6"DDD_D]*XN1[DHK&C)?&]N,GG.41(1M/!8TU.K:-![!6F]<F5V)W/(>?
M_P"<,5TX_P!V3OY6LCE?F;?$_C0[*\WFU6"V3+S?+@Q:K3;VE/3I\E8;;;0@
M$DE1]5+I-O"&'))99\ZV_NX\;=C=W,LWMP4FSSY*8MC\3FJ'$0&VUGNZR%*'
MH-;%,=D$C#OGOL;['6^5U#5NW$N^>3CX-FVSQ6[WRY25<`A:V?E8Z=>6JUO'
M0>@T7OICR=X_1[NR$+Q1QQ[*L3D.`AV1?8#[G>%NR4+/[IJQ_B_H50_)+U)<
M?/!Y;59I:']V\'MOB9AC['^DMM83[UR@-C^,2!S>9'+\)/#LK.XMV'M>AI\O
MC[ENCJ0Y`I<0%I)4DZ*!XZ^WMX5I_P#HRL?N7Z<3QY_%V\>WC7#I3@.?'[OL
MH.BH;.;E)VASZWY\G&X^4S;1'?;ML"2Z6FVGGD](>!`.JDCE4+:U..,X)U6J
MN6=1>]Z_.+<]\,$F8+?=N;?;&I$AB7"NS,I3CL5]A74E:0I/;R/'E5-/%5;R
MF77<OW(X:&9JT6"#JH*[!R(U[::71]15Z="='R.[H_T_V9AV.?*\:_[>O"R3
MPHZK5'0-8B^\@M:#7O%9/*ALEZ,V.)9OA]!#//SO^8,9&R&*3^B=<4)D9Y+8
M5_%15:%J$2.2GN!6/P>%6\.G/W2*>;?C[4R*,=R4E6@U(2"H@#F=`.0'$FM#
M)F^B-C9;S=<=N]LR"Q3%VZ\V:2U,MD]HZ*;>:4%(([QJ-".T4.*::81DT\KL
M?0UY>]Y[5O?MQ:LKAE#-Y8`AY5:DG546>T-'$Z<^E6G4D]HK&MKV/!NTVJR.
M1<@=:J3+2M=`8G]H3QV%3I_6&V?RPIKA_F)<[^)D(\D_W.^>P-JU/LK32,G4
M^F7:T:[;8)H?\A0>/]I36'8LR9OU?BA&<.\K.&8=OEE.\T,-N*O+779,?\,!
MJW37P1+D-GEJX"0`![NITJZ=\I042N/&C&;D>OG(&GEOW*UX:QH8_P#>L5SC
M+%B#E9=3/G^2#TI/84C0UKF(A:-K_,!NALW;KG:MO[O'MD*\24RYZ'XK;Y4X
MA)2-"M)TX&JYTQF\LNJNG6L(4_\`7C\R']:[?^;F/Q:K^+7X+/EV^3091YO-
M]\SQZ[XMD&1PI5EOD=46Y1T066U*:5IJ`M*01RKJXT(O*./E3DL,;.D!"0A/
MPI`"1W`</N4PA;'06S"O,5O/MUCT7%<,S9ZR6"$IQ<:`B-%<"5.'51ZG&5*_
M=JJ549/+1=&Z<5A/!S.;[M[F[CI#6<9S=<AB=05]7O.!J)U#D3'9"&R1V:I-
M=C7&.B(RNG+I)G%6JUW6_P!TA6*Q6R1>KU<G$LV^T1$%;SKBSH``GD#VD\JG
M)I=65Q6?M0\3>G:Z]^7?8G#</F/-)R3=JY.S]QWF23HU;D-JB6]"]>+;9?45
M_A*/<!2M<U;-OP.6UNJ&/.HTC%SKEF)ZGG>[?P_\PW3,M&*PZ-'U`*2%`@I"
MDJ&B@>(([B*PGY/0D*GG3\MRMM+\[N;AT'3!,EE$WF(RGW;7/>)43H.3+Q)(
M_!5J.6E:7%OW=&9/,X^W[D,/U'+EH.VG!1E%J"4*4>P<-.9/8D>N@X/EQ3R"
M[L97C-BR9.26.S(O\%F>S;)33ZGF6Y"`XA+A2H#JZ5#4:<#2KY<8L;API264
M\'0?LY=V>W-\<([=6)'X]<^9$E\"7D:-NYM7D>S6;3,&RAUB5/CQV9<>X10M
M,>2R\D$*0%'75).A[C5\+%9'*%K*W7+#.O\`+WOK<MA,DR2^0H9N<>_61^`J
MW=6B/FT`JAO*UUX(7H%:<>GA7+ZE9@E1:ZLL1:\7BZ9!>+GD-[FKN%YO4ER;
M=+@Z=5./.DE2E:]@UX#LJQ)16$42;EU9)[Y$_+M#EV*Z[L9U9VYC&31'K7B=
MJEHU!M[H*'Y12>UX$I0?P:0Y5V.B-+A\=8<GW&0>8?9VX;(;F7;%7$.+Q^?U
MW'#[@H$AZ"M6GAE7X;)/2JFJ;%**?<3NJ=<F;WRQ;Y/[&;CQ[I-?<_H3D7AP
M<RB)XI0UJ`W,"?PF-=3WIU%%]7N+U)<:[VWZ=SZ!X,R+<8<6?!D(E0IK2'XD
MEI04AQMP!25)(Y@@UD8QT-I//4RZ#HWWS'[+S-]MO1A,&_LXV^+E%GFX/QS)
M3I'6%E/0E:.)[]:MHMV2R4<BIVQQD8BY]FGD3C:T#=NWZJ!`)M;ITU&G_>-:
M;^:GV$G_`(_U)3L2LKF-8OC^/O24S';+`CPG)24]`<+*`@J"=3IKI2#:;;1I
M16U)'0ZCOKA(2G>[;F1NUMCE&WT6[-V21D+3+;=T<:+R6BT^V]J6PI).O1IS
MJ==BA)-E5T'.+2(Z1]FKD6@__6K?R'^2G?\`"*=7-6,8$/Z]^2O[-7(OTM6_
M\UN_S]<^<O`?U[\A^S5R+]+=O_-;G\_7?FKP'P'Y*?LULB_2W;_S6[_/T?.7
M@/@/R5_9JY%^EJW_`)K=_GZ/FKP']>_(?LU<BXG_`&MV_7L_Q4X?_D5SYR\!
M_7OR=3C_`-FQ:6I#2\JW/G3XP(+L>UQ&HQ5W@*=\;3Z*Y+G/LB4>`N['M[6;
M![6[-Q^G"<99C7%:.B3?I),B>[KP.KSFJD@]H3H/12D[I3U?0=A3&&B$S\T7
MEON'F&CX<Q`RR/BYQ=^6ZZI^*N3XPDI:`">EQ'3IX9^FK./>JL]"OD\=W8ZC
M5K3]G%D-MO%GNBMUK>ZFUSXTTLBUN`K##J7"D'Q^&O3IK3#YJ:T%5P&GG)*T
M2/W.-9^NAIFCR3'+-EUANV,W^"W<;+>XZXMQA.#5*VUC0^HCF/374W%Y1R45
M)89%Y/\`LUKD9\TVG=6,Q:U/N&W1Y5N6X\VP5$MH<6EY(4I*=`3H-:?7.7@S
MI<!MZF;C_P!G!/@9!8[A>MS(=TLUOG,2;K;&K<XVN0RTKJ4TE:GE!)5ISTKD
MN;V2"/`P\MDJ#*$-(0VVA+;:$A+;:0`$@<``!V"D-7EFEH7JY5T!G_F?\K"/
M,%*Q2[6[(V<5OF/)>C2)KT94E,B([JI+6B5MD%*SU`ZTQQ^1[64*\CC>]AZ,
M:J?LULB_2U;Q_FMW^?ICYR\"O]>_)LK+]FU+8O%K>OVY\:X61F4VY=K='M[C
M3LB.E0*VDNJ>5T%0X:Z5&7-36,$X\!]')DI5NMT&T6^%:K;&;A6ZVL(CP8C0
M"$-M-`)0E*1P``%(2ZO+-"*PL(0;S';`VC?[#HUC=G(L=_L\E,O'LB+7C&.H
M^ZZVM`*2I#B-01KSX]E6T7;)9*;Z?<C@8W^S5R+0`[M6_0\Q]5.Z<>?]\4Y\
MY)YP)?U[?<?QY?-LLNV@P-C!<GS"/F<6T.J3CLYJ.N.XQ#/*.OK<<Z@@_"1I
MPI.VR,Y92P/TUN$<-Y%UJLM$AW7RO(<5BXR_CJ1(E3;GX#UO*`LR$!!5X0U&
MH)(X:4GR[9UQBX^>I?1#>V84K<-R[2-M9F.R@U;<EN*XEYBN)2IQ);;)6RK4
M:I4E0T-1GR,N#7=@J\;D^R,'/]Q+W9,HBQ+$W\Q9\;0U,S=24)5TLR%I0A`4
M0="`>KA7+[Y1GB&BU)55IQ>[5Z%-QKOG5EAJRJPY5$:Q^6N&W#MAB(<6GYA2
M4=?BJ!UU*M:YR)S7WI_;]`IC%O:UU/:X73/,8=PN)=LCC7=[(K\U&?=:BH9'
MRJVU$M].AXZZ<177.R#@G+5]>G;`149)X6A;&N^X&?3[Q+Q6]1,7QVSRW(,%
MYV.)#LQUDZ+4KJUZ4@\.%"G;>\Q>$G^YQ[:TL]S177<G,8F*7UA8CQ<UQ>[1
M;?,+:`MB4E]7Y-24JUT\3EPJN?)L]MK2:>"2I65ZK)NKAN=+N6,8[=;*OZLN
MCE^AVK(K>ZA*G&%.$AUM25`Z=0&H-3ER=T$X^4F<5.V33\9,W=#-\ALLVWVC
M$6?FKE&97=[ZCH2OIM[!`6GW@="O7A4N5?*#2CKJ_H<I@FFV9^6YK+;L>$7K
M'):41\BNL)EY?0EP*8?!ZT^\#H1IIK4K[GMC*/=G*ZNK3[(5GO\`1PIMM:%&
M1"LDW)N>+;FLVF<KKQ%<-CYY0;!,5Q]:DI>4L#7IU3H=3VTA;RG7=M[=QB-.
M89,2/N?<[YN#)M5F6!BT6VSS&D>&E0ER8K?474+(UZ$J(`TYUQ<J4K,0_'#.
M^UMCEZG.8YE^6WR!:YK^[-CMLV<H!5H>B,EY!+G3X9T`XG3AZZA7=.:B_<2S
MV).$%_Q9T[$[<S(LGS&WV/*8=LCXS)98:BRH:'0Z5LI4K50`(!55D7;*<DIK
MH1:A%)M&--W)R1>.:+0U:<HLV20[-?FVP'&EH=/%;?5KH%@@BHRY,G'KT:EA
M@JHJ7HUE&\D7G-\RR._VG#[I&QJR8R^(<N[.L"0[(E!(4M*$JX!*==-:L<[+
M9N,7A+N14807W+4Z"-><FQ;%+W=<\>@NR+0%F),AZI$EL#\F5(Y!2E'3058I
MSA6W9V[D7&,I+::3;',L@O+5XM&7I$?)("$3V6NA*.J'*1XC1Z4@`].NAJOB
MW3GE3UU7T)6UI8:.@VNO]UR3&G+A>9`DS!/EL!Q*$M@(:=4A`T2!V"K>)8YP
MR_+(W04981ML[RH8=C4R])C_`#<E"D,0(NN@<?>5T-I)[M>=2Y%BKCG4C".Y
MX$Q3<-P[1/MKE[S['FY4A;2[GC,II#(:86>/AK!"BH#Z:6WW1:W26?'H6X@U
MTCGU/!V_9S>,JS*WV[-K;CMOL$I+49B;&:7UI4CJX+.AT';SKCG9*<TI8VL[
MLC&.6CRA[H9/=<>L5OMT:([F-_N<FUQ9^A,/PHI(7,">U)`X"N0Y4VDL=6\9
M_P!3KIBI/PC;O7G/L#NED<RN\1<HQV]RVX$F0S'$=V&^\=$*]WXD:\.-2WV5
M..]Y3(J,+$\=D=1MUD%UR!&5?6LA+YM=[DPX12A*.EEL^Z#T@`\.^K^/9*>[
M+[D;8J.,=T)8WG6;W*U8FU"OL>WW&_7ZXV]ZXNL-K;2U'*O"!24Z<-*3?(G*
M*VO#<FBWVDNK6=#O<-R7)F\PNF%9'<H>0N1H2)\:\P6PWTA2@DM.I2>D'CK3
M%-D_<<)/.%G)79%;5)+`L.HXGLYZTZ4"<YS8+K>[A@TFVM(=:L=\:G7)2EA!
M2RA)!*0>9]%+7UN4HX[/);7/:GZHXJ][9SXN?V;*\;;2NU?.&;>K/X@;2B2$
MG1YM)X>_R.E46<64;5..F<M>I;"U.&V1C6K9^9>&+I=,MO=QMM[R.0Z]=8%N
MD`1RVI1\-"P!HK1/?48\/=ES;RW^F#DK\82T121A>:2=M4X?)C,R+C9[I'3;
M'_&2$O067DK0HG3@H)&A%=E3-U;7V9U614]R.YS7'+O>)N`OVV.VZBP7=J7<
MNM83TM(04DI!^+C5]M;DX-+.'U_8KKFDI>IRT:R[A8'<+S&Q.TPLGQN[RW)T
M./(D?+NQ'G3JM!UX*2352A93E02:;_8EF%B^[5&KF[;98_CERDRG(\_+LDOL
M&YW5MIP-LL,QG`0TTH\RA/TU"7&L=;SAR;S]#L;5E+LD;#.-KYEQR*R9-CVB
M'%SH;N36XK\-M],=84'QV%:0"#KSJ=_&<IJ<?*S^@5W?:T_T"/M?<LBN^19+
ME-TGV.?=9"V(D*V20`+>@=+:'%`<>K4DBHKC.<G*;Q]/!QW8BHI&@?P#.+=8
M&,<M\)FZQL:R-BY8V^](2WXT1*5**'!]Z0K2H2X]BCM75)Y1-6P<LMZH5K&K
MIG\VX.-91C$&S6\-*4W*C2_'47-1HDI[M":;KG;)_<L(7DHXZ&CFX3)N^>9#
M.ND-MW&KU8&[:I9<!670X5'1'9H.(-1E0Y6-M=&B?N?]:7<P7\`DVW),;-AA
MMMX]9,?GVWK+@"P\^G1&HYDJ/,U%\=J:VZ*+7[DO=4D\ZMHXG&\5S>PVVUV]
MS:W&[C*MZAK=GWVB^HESK"RK37J`/#U51559%);%T[DY61>?N9T,>V[G8]DV
M7W&PXW;K@QDLAF0B1+F='0I#*4D=(TU`5K5D5;&4FHKJ1S6TDVS%F;9Y(C&@
M"ZQ=<IN^20[U?7`KPVDH:5Q0V5:\$#0"HRXTXPUR]V6=C:MWIC"-W)L>;X=D
ME_N^'0(F16;)WA+F6F0]X#L>40`I;:N12K34U:Z[*YMP68OMZD5*$UB3?0U]
MYQ;<;-HUHLN5F'#M4J>N=>%VY8"XK+8'@QTDZ]:NKCU57.JZW$9X2[X!2KAU
M75GH=L[IC.36+),;N$V_+"EP[\S<Y(4OY)Q.@\-2AK[I[*D^/*$U*#SV>0=V
MY-/H86*Q-UL.MSUG@XA;9\;YU^0W+=FA"RA]TKXI&FA`-1J5M?VJ"P2L<)O.
M>PIV:XN[F6*2+.X\+=<'/"D17A[R6931"T^L!5,VU^Y'#Z,IA-0EGL(]?</S
M_-?EH%\PZQ0;BVIA$S-0Z''2TR0K\F@>][VG$<J5E199A3BOKZ%ZG"/5-]>Q
MNGMHH^0WK/I.206D)N[R#C5T2OJ=:2&]"KIY<%=]=7#WN3EWT(^_A+!XM8/F
MKEAQMUN/`M>6X#)4FSNMJ3\I/C*&AZ@D#H*Q\6O;1[-C@NGW1_\`)SW8[GU>
M&;)VR9_G5RLB,MM4'&L?L<MN=(BQW_F'9;[)U0G4?"C7C4G79;);XI1U.9C6
MGMZY1YHLVXN%W;)6\3M$#(+1DDU<^(_(?\!<1YT>\E8^^2#Q%<5=M4I**33T
M);H32W-]#3N;37)=KP"R3FVKK%@7&5.RM:'2T.J4"I0;TT)`4:B^*VHQ?ZG5
M<DY-,6?&L.QO$D2&[!:VX/S1ZI+VJEN.$<NIQ9*C]-.U4PKSM11*;GU9U-6D
M#R[O57>QSL!Y'VU&.K.R*'XCZ_WJ+/Q9V.A<.9KB[@]"T?"GVUV7Y(@@5R5Z
MOWJ%JP14=OLKO<ZM2O:FNA+5%AYCUC]^HP_$G$N'Q?1^_0M60\`.WUBNK4EW
M/0\JYW.(L/9ZZX1+4_\`#Z:Y#_0DM6!^+VC]^K&'8.Q7K%0CJR+_`!+SR5[:
MDR;+5<_:*XCI17;ZC7(Z(@^Y</O?57%V.%5\O95B)Q+4]GJ%50U8/4IW>NIS
M[?4@M$53\1]OW:ZM";*]M0C^3(L*[_R_0DRWM/LJ4NQ%_P"A>GG7078OKAT_
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
